Jieduquyuziyin Prescription Alleviates SLE Complicated by Atherosclerosis via Promoting Cholesterol Efflux and Suppressing TLR9/MyD88 Activation

The study demonstrates that the Jieduquyuziyin prescription (JP) promotes cholesterol efflux and inhibits TLR9/MyD88 signaling, reducing the risk of systemic lupus erythematosus (SLE) combined with atherosclerosis (AS). Using pristane-induced apolipoprotein E-deficient (ApoE−/−) mice, the research provides in vivo and in vitro evidence supporting JP's potential as a treatment for SLE with AS. The findings suggest that JP could be developed as a candidate for treating SLE atherosclerosis, though further research is needed to confirm the exact mechanisms.